* e1. score ≥ 6 on the who 11-point clinical progression scale at screening * e2. respiration rate \> 30 breaths/min in adults under low-flow (⩽ 6 l/min) oxygen * e3. liver failure of stage 3 according to the child-pugh classification * e4. severe renal failure (≥ grade 3 according to kdigo classification) * e5. treatment with anti-sars-cov-2 immunoglobulins or any blood-derived products in the last 90 days * e6. any anti-sars-cov-2 vaccine injection performed less than 21 days before screening * e7. pregnancy or lactation. women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study * e8. known allergy or hypersensitivity or intolerance to study product components * e9. history of anaphylaxis during a prior administration of equine serum (i.e., anti- tetanus serum or anti-ophidic serum or anti-arachnid toxin serum or anti-rabies serum) or allergic reaction due to contact or exposure to horses * e10. participation in any other interventional study with an investigational product in the last 30 days or within 5 half-lives of receiving the investigational product * e11. patients with short life expectancy or with any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study * e12. septic shock

* e1. score ≥ 6 on the who 11-point clinical progression scale at screening * e2. respiration rate \> 30 breaths/min in adults under low-flow (⩽ 6 l/min) oxygen * e3. liver failure of stage 3 according to the child-pugh classification * e4. severe renal failure (≥ grade 3 according to kdigo classification) * e5. treatment with anti-sars-cov-2 immunoglobulins or any blood-derived products in the last 90 days * e6. any anti-sars-cov-2 vaccine injection performed less than 21 days before screening * e7. pregnancy or lactation. women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study * e8. known allergy or hypersensitivity or intolerance to study product components * e9. history of anaphylaxis during a prior administration of equine serum (i.e., anti- tetanus serum or anti-ophidic serum or anti-arachnid toxin serum or anti-rabies serum) or allergic reaction due to contact or exposure to horses * e10. participation in any other interventional study with an investigational product in the last 30 days or within 5 half-lives of receiving the investigational product * e11. patients with short life expectancy or with any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study * e12. septic shock

e1. score ≥ 6 on the who 11-point clinical progression scale at screening e2. respiration rate > 30 breaths/min in adults under low-flow (⩽ 6 l/min) oxygen e3. liver failure of stage 3 according to the child-pugh classification e4. severe renal failure (≥ grade 3 according to kdigo classification) e5. treatment with anti-sars-cov-2 immunoglobulins or any blood-derived products in the last 90 days e6. any anti-sars-cov-2 vaccine injection performed less than 21 days before screening e7. pregnancy or lactation. women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study e8. known allergy or hypersensitivity or intolerance to study product components e9. history of anaphylaxis during a prior administration of equine serum (i.e., anti- tetanus serum or anti-ophidic serum or anti-arachnid toxin serum or anti-rabies serum) or allergic reaction due to contact or exposure to horses e10. participation in any other interventional study with an investigational product in the last 30 days or within 5 half-lives of receiving the investigational product e11. patients with short life expectancy or with any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study e12. septic shock

e1. score ≥ 6 on the who 11-point clinical progression scale at screening e2. respiration rate > 30 breaths/min in adults under low-flow (⩽ 6 l/min) oxygen e3. liver failure of stage 3 according to the child-pugh classification e4. severe renal failure (≥ grade 3 according to kdigo classification) e5. treatment with anti-sars-cov-2 immunoglobulins or any blood-derived products in the last 90 days e6. any anti-sars-cov-2 vaccine injection performed less than 21 days before screening e7. pregnancy or lactation. women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study e8. known allergy or hypersensitivity or intolerance to study product components e9. history of anaphylaxis during a prior administration of equine serum (i.e., anti- tetanus serum or anti-ophidic serum or anti-arachnid toxin serum or anti-rabies serum) or allergic reaction due to contact or exposure to horses e10. participation in any other interventional study with an investigational product in the last 30 days or within 5 half-lives of receiving the investigational product e11. patients with short life expectancy or with any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study e12. septic shock